Baricitinib Shows Durable Responses in Refractory cGVHD (Targeted Oncology) - Aug 31, 2026 - "In an accompanying editorial...Paul A. Carpenter, MD...noted the failure of other treatments to replace steroids as first-line therapy, and proposed that if baricitinib's efficacy is confirmed in larger phase 2 studies, the favorable safety profile 'may place baricitinib as a strong contender for cGVHD prophylaxis or first-line therapy studies.'"
Audio
|